Conditions: Age Related Macular Degeneration Choroidal Neovascularization Macular Edema
Keywords: choroidal neovascularization macular degeneration macular edema intravitreal bevacizumab vegf verteporfin PDT
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 22
Healthy volunteers: no

Brief summary:
To evaluate safety, visual acuity outcomes, persistence of choroidal neovascular leakage, and the number of treatments of combination intravitreal bevacizumab and verteporfin photodynamic therapy at standard or reduced fluence level in patients with subfoveal CNV due to age-related macular degeneration.

Detailed description:

Arms:
arm 1: Patients will receive combination verteporfin with photodynamic therapy at reduced fluence \[300mw/cm2\] followed by intravitreal bevacizumab (1.25mg) on same day following photodynamic therapy. arm 2: Patients will receive combination verteporfin with photodynamic therapy at standard fluence \[600mw/cm2\] followed by intravitreal bevacizumab (1.25mg) on same day following photodynamic therapy.

Interventions: intervention 1: Bevacizumab intervention 2: verteporfin photodynamic therapy reduced fluence intervention 3: verteporfin photodynamic therapy standardfluence
Intervention descriptions: intervention 1: Patients will receive intravitreal bevacizumab (1.25mg) on same day following photodynamic therapy. intervention 2: Patients will receive combination verteporfin photodynamic therapy with stand fluence \[600mW/cm2\]. intervention 3: Patients will receive combination verteporfin with photodynamic therapy at standard fluence \[600mw/cm2\].

Protocol document: